SciELO - Scientific Electronic Library Online

 
vol.61First report of an autochthonous human visceral leishmaniasis in a child from the South of Minas Gerais State, BrazilMurine typhus in Mexico City: report of an imported case índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Revista do Instituto de Medicina Tropical de São Paulo

versão On-line ISSN 1678-9946

Resumo

MUCENIC, Marcos et al. Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review. Rev. Inst. Med. trop. S. Paulo [online]. 2019, vol.61, e12.  Epub 14-Fev-2019. ISSN 1678-9946.  https://doi.org/10.1590/s1678-9946201961012.

Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment after liver transplantation. However, pegylated interferon may still be required for genotype 3 non-responders. We treated a liver graft recipient with grade 1 fibrosis in the biopsy with daclatasvir and sofosbuvir for 12 weeks. He did not respond and progressed to grade 3 fibrosis. Lacking other options, we obtained a sustained virological response with pegylated interferon, ribavirin and sofosbuvir for 12 weeks. The combination of pegylated interferon, ribavirin and sofosbuvir is a viable option after the failure of direct acting antivirals in economically disadvantaged countries.

Palavras-chave : Hepatitis C virus; Liver transplantation; Treatment.

        · texto em Inglês     · Inglês ( pdf )